North America small molecule contract development and manufacturing organization (CDMO) market is projected to grow by 5.3% annually in the forecast period and reach $ 42,793.3 million by 2031, driven by the increasing demand for small molecule medicines and therapies, a rising demand for cost control in drug development, the increasing incidence of disease, and rising healthcare expenditures.
Highlighted with 24 tables and 48 figures, this 103-page report “North America Small Molecule Contract Development and Manufacturing Organization (CDMO) Market 2021-2031 by Product Type (API, FDF), Service Type (Preclinical, Clinical, Commercial), Customer Type (Pharmaceutical Firms, Biotechnology Firms), Therapeutic Area (Infectious Diseases, Oncology, Ophthalmology, Cardiovascular Disorders, Central Nervous System, Respiratory Disorders, Metabolic Diseases), and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire North America small molecule contract development and manufacturing organization (CDMO) market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2019-2021 and provides forecast from 2022 till 2031 with 2021 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces
The trend and outlook of North America market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19 and Russia-Ukraine conflict. The balanced (most likely) projection is used to quantify North America small molecule contract development and manufacturing organization (CDMO) market in every aspect of the classification from perspectives of Product Type, Service Type, Customer Type, Therapeutic Area, and Country.
Based on Product Type, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
• Active Pharmaceutical Ingredients (API)
o Branded Drugs
o Generic Drugs
• Finished Dosage Formulations (FDF)
o Oral Solid Drugs
o Injectable Drugs
o Semi-solid or Liquid Drugs
o Other FDFs
Based on Service Type, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
• Preclinical Use
• Clinical Use
o Phase I
o Phase II
o Phase III
o Phase IV
• Commercial Use
By Customer Type, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
• Pharmaceutical Firms
• Biotechnology Firms
By Therapeutic Area, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
• Infectious Diseases
• Oncology
• Ophthalmology
• Cardiovascular Disorders
• Central Nervous System
• Respiratory Disorders
• Metabolic Diseases
• Other Therapeutic Areas
Geographically, the following national/local markets are fully investigated:
• U.S.
• Canada
• Mexico
For each key country, detailed analysis and data for annual revenue ($ mn) are available for 2021-2031. The breakdown of national markets by Product Type, Service Type and Therapeutic Area over the forecast years are also included.
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Selected Key Players:
Boehringer Ingelheim
Cambrex Corporation
Catalent
Cipla
Covance Inc.
Lonza Group Ltd.
Medley Pharmaceuticals
NatcoPharma
Patheon (Thermo Fisher Scientific, Inc.)
Piramal Pharma Solutions
RedHillBiopharma
Siegfried Holding AG
STA Pharmaceutical
Sun Pharmaceutical
Teva
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
